Brno, 26. 01. 2017
Application for junior group leader position at CEITEC MU
Mgr. Michal Šmída, Ph.D.
CONTENT
1. CV…………………………..p. 1
2. Professional experience….p. 4
3. Grants………………………p. 5
4. Publications………………..p. 6
5. Research career…………..p. 8
6. Research plan……………..p.10
7. Referees……………………p.12
Junior RGL application M. Šmída
1
1. CURRICULUM VITAE
PERSONAL DETAILS
Date of birth: 01. 02. 1976
Place of birth: Boskovice, Czech Republic
Gender: male
Nationality: Czech
Marital status: married, 2 children
Work address: Central European Institute of Technology – Masaryk University
(CEITEC MU)
Kamenice 753/5, building A35, CZ-62500 Brno, Czech Republic
Phone: + 420 549498194, + 420 736722290
E-mail: michal.smida@ceitec.muni.cz
Researcher ID: J-5046-2014
CURRENT POSITION
Senior researcher at CEITEC MU (1.0 FTE)
OTHER FUNCTIONS AND POSITIONS
 Deputy head of Medical Genomics research group, CEITEC MU
 Research assistant at the Department of Internal Medicine – Hematology and
Oncology, University Hospital Brno
 PhD supervisor at Faculty of Medicine, Masaryk University, Brno
 Member of Economic committee at CEITEC MU
 GMO responsible person for Molecular Medicine, CEITEC MU
EDUCATION
2008 Ph.D. in Natural sciences, Thesis: „Biochemical and functional
characterization of Fyn-PAG association and its role in T-cell anergy”
Institute of Molecular and Clinical Immunology, Magdeburg, Germany
2002 – 2007 Doctoral studies at the Institute of Molecular and Clinical Immunology, Ottovon-Guericke
University, Magdeburg, Germany
2002 Mgr. (~M.Sc.) in Molecular Biology and Genetics
Faculty of Science, Masaryk University, Brno, Czech Republic
1997 – 2002 Faculty of Science, Masaryk University, Brno, Czech Republic
1994 – 1997 Faculty of Medicine, Masaryk University, Brno, Czech Republic
SCIENTIFIC BACKGROUND AND EXPERTISE
 Immunology
 Hematooncology
 T-cell signaling
 Cancer biology
Junior RGL application M. Šmída
2
 Functional genomics, synthetic lethality
 Molecular biology, CRISPR/Cas9 technology
 Lentiviral production and infection, Cell culture
CAREER-RELATED ACTIVITIES
 Supervisor of PhD students, diploma students and technician assistants
 Tutor at the practical courses and seminars for students
 Postdoctoral representative at CeMM, Vienna (2011-2014)
 Co-founding member of the “Vienna Area Postdoc Association” (VAPA)
 Co-organizer of the Postdoc Retreat for postdocs in Vienna area
 Associate member of AACR (American Association for Cancer Research)
 Member of EHA (European Hematology Association) and ERIC (European Research
Initiative on CLL)
 Trainee at the Grant writing course, Leadership course and Mentoring program
OVERVIEW OF ORAL AND POSTER PRESENTATIONS
 58th
ASH annual meeting, San Diego, USA – poster presentation (2016)
 2nd
International Conference on New Concepts in B-Cell Malignancies, Estoril,
Portugal – poster presentation (2016)
 AACR Precision Medicine Series “Synthetic lethal approaches to cancer
vulnerabilities”, Seattle, USA – poster presentation (2013)
 The 3rd
EMBO meeting, Vienna, Austria – poster presentation (2011)
 EMBO Workshop on “Synthetic Lethality: From Yeast to Man”, Vienna, Austria –
poster presentation (2011)
 13th
Joint Meeting of the Signal Transduction Society (STS), Weimar, Germany – oral
presentation (2009)
 2nd
European Congress of Immunology, Berlin, Germany – oral presentation (2009)
 37th
Annual Meeting of the German Society for Immunology, Heidelberg, Germany –
poster presentation (2007)
 Joint meeting of European national society of immunology, Paris, France – poster
presentation (2006)
 9th
Joint meeting in signal transduction – Receptors, mediators and genes, Weimar,
Germany – oral presentation (2005)
 Joint 36th
annual meetings of the German society of immunology and the
Scandinavian society for immunology, Kiel, Germany – poster presentation (2005)
 Joint Annual Meeting of the German and Dutch Societies for Immunology, Maastricht,
the Netherlands – poster presentation (2004)
 6th EFIS Tatra Immunology Conference, Tatranske Zruby, Slovakia – poster
presentation (2004)
PUBLICATIONS
Author of 15 publications, many of which were published in journals with impact factor >10.
Currently 1 pending first-author publication and few co-author publications under writing.
Junior RGL application M. Šmída
3
Cumulative IF = 111.64
Average IF of top 5 publications = 14.15
Total sum of citations for all publications so far: 454
H-index: 10
(see part 4 for list of publications)
Junior RGL application M. Šmída
4
2. PROFESSIONAL EXPERIENCE
2015 - present Medical Faculty of Masaryk University and University Hospital
Brno, Department of Internal Medicine - Hematology and Oncology
Research assistant
2014 - present Central European Institute of Technology – Masaryk University
(CEITEC MU), Brno, Czech Republic
Senior researcher, Molecular Medicine program
2010 – 2014 Research Center for Molecular Medicine of the Austrian Academy
of Sciences (CeMM), Vienna, Austria
Senior post-doctoral fellow (Dr. S. Nijman)
2007 – 2010 Institute of Molecular and Clinical Immunology, Otto-von-Guericke
University, Magdeburg, Germany
Post-doctoral fellow (Dr. J. Lindquist)
2002 – 2007 Institute of Molecular and Clinical Immunology, Otto-von-Guericke
University, Magdeburg, Germany
Ph.D. student (Dr. J. Lindquist)
1997 – 2002 Faculty of Science, Masaryk University, Brno, Czech Republic
Undergraduate student (diploma thesis with Dr. Vitek)
1994 – 1997 Faculty of Medicine, Masaryk University, Brno, Czech Republic
Undergraduate student
Teaching activities
 At CEITEC MU
 Supervisor of 4 PhD students (1 at CEITEC PhD school, 3 at the Faculty of
Medicine); 1 PhD student received PhD talent award.
 Supervisor of 2 diploma students (1 finished in 2016) and 1 medical student (within
the scope of P-PooL program with extended research activities).
 In the past
 Supervisor of 3 PhD students and multiple diploma students (students of medicine,
molecular biology and systems biology)
 Supervisor of several technician assistant candidates during their lab rotations
 Tutor at the practical courses for medical students, systems biology students and
seminars for systems biology students
Junior RGL application M. Šmída
5
3. GRANTS
 „Resistance to monoclonal antibody therapy at B-CLL and B-lymphomas: its
foundations and potential intervention strategies“, AZV (Agency for Biomedical
Research, Ministry of Health of the Czech Republic) grant nr. 15-33561A (2015-
2018), cca 10 mil. CZK
 „Chemical-genetics to uncover lung cancer vulnerabilities”, submitted for Stand-alone
grant of the FWF Austrian Science Fund in 2013, applicant turned grant down due to
accepted position at CEITEC MU, Brno, Czech Republic
Thanks to the received grant of AZV that is fully covering the PI´s salary and material
expenses, the applicant could use the temporary freedom to attempt to obtain some of the
prestigious mainly foreign grants:
 EMBO Installation grant (150.000 € total) – passed to the second round of selection
(personal interview)
 Neuron Impuls (1.000.000 CZK total) – passed to the second round of selection
(personal interview), finally ranked on the 2nd position
 EHA Non-clinical advanced research grant (160.000 € total) – first decision expected
in March
The research project on functional CRISPR/Cas9 genomics submitted for EHA research
grant will also be submitted for GAČR grant this year.
As part of our newly initiated collaboration, we are team members on the current AZV grant
application of prof. Veselská (Department of Experimental Biology) (budget for expenses and
part-time PhD student).
Within the collaborative project with prof. Mayer (IHOK, University Hospital Brno) on CAR-T
cell therapy (see below), we have recently recruited a joint postdoc who applied with this
project for Marie-Curie and SoMoPro fellowships. We are also currently debating with other
CAR-T cell researchers in Germany to apply jointly for an H2020 grant in the future.
Junior RGL application M. Šmída
6
4. PUBLICATIONS
Author of 15 publications, many of which were published in journals with impact factor >10.
Currently 1 pending first-author publication and few co-author publications under writing.
Cumulative IF = 111.64
Average IF of top 5 publications = 14.15
Total sum of citations for all publications so far: 454
H-index: 10
Pending publications
1. Smida M, Kähne T, Merida I, Naumann M, Schraven B, Lindquist JA. IGAP, a novel
Inducible Rac/Cdc42-GTPase-Activating Protein, regulates T-cell activation and
migration. In preparation
Publications
1. Smida M, Fece de la Cruz F, Uras IZ, van Jaarsveld R, Konopka T, Nagy-Bojarszky K,
Muellner MK, Bago-Horvath Z, Haura EB, Loizou JI, Nijman SMB. MEK inhibitors block
growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors. Nature
Communications. 2016 Dec;7, 13701; IF=11.329, times cited=0
2. Smida M. Chimeric antigen receptor (CAR) T cells: gene therapy of the future for
malignant diseases? Klinická Onkologie. 2015. Czech.; no IF
3. Doubek M, Smida M. Treatment of chronic lymphocytic leukemia with monoclonal
antibodies, where are we heading? Expert Rev Hematol. 2015 Aug 26: 1-22; IF=2.439,
times cited=0
4. Bürckstümmer T, Banning C, Hainzl P, Schobesberger R, Kerzendorfer C, Pauler FM,
Chen D, Them N, Schischlik F, Rebsamen M, Smida M, Fece de la Cruz F, Lapao A,
Liszt M, Eizinger B, Guenzl PM, Blomen VA, Konopka T, Gapp B, Parapatics K, Maier B,
Stöckl J, Fischl W, Salic S, Casari MRT, Knapp S, Bennett KL, Bock Ch, Colinge J,
Kralovics R, Ammerer G, Casari G, Brummelkamp TR, Superti-Furga G, Nijman SMB. A
reversible gene trap collection empowers haploid genetics in human cells. Nature
Methods. 2013 Oct;10(10):965-71; IF=25.328, times cited=42
5. Smida M, Cammann C, Gurbiel S, Kerstin N, Lingel H, Lindquist S, Simeoni L, BrunnerWeinzierl
MC, Suchanek M, Schraven B, Lindquist JA. PAG/Cbp suppression reveals a
contribution of CTLA-4 to setting the activation threshold in T cells. Cell Commun
Signal. 2013 Apr 19;11(1):28; IF=3.661, times cited=7
6. Smida M and Nijman SM. Functional drug-gene interactions in lung cancer. Expert Rev
Mol Diagn. 2012 Apr;12(3):291-302; IF=3.333, times cited=5
7. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, CraigMueller
N, Colinge J, Duernberger G, Nijman SM. A chemical-genetic screen reveals a
mechanism of resistance to PI3K inhibitors in cancer. Nature Chemical Biology. 2011
Sep 25;7(11):787-93; IF=12.709, times cited=92
8. Beyer T, Busse M, Hristov K, Gurbiel S, Smida M, Haus UU, Ballerstein K, Pfeuffer F,
Weismantel R, Schraven B, Lindquist JA. Integrating signals from the T-cell receptor and
the interleukin-2 receptor. PLoS Comput Biol. 2011 Aug;7(8):e1002121; IF=4.587, times
cited=11
Junior RGL application M. Šmída
7
9. Börner C, Smida M, Höllt V, Schraven B, Kraus J. Cannabinoid receptor type 1 and 2mediated
increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem.
2009 Dec 18;284(51):35450-60; IF=4.258, times cited=43
10. Börner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Höllt V, Kraus J.
Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J Immunol.
2009 Jul 15;183(2):882-9; IF=4.985, times cited=63
11. Simeoni L, Lindquist JA, Smida M, Witte V, Arndt B, Schraven B. Control of lymphocyte
development and activation by negative regulatory transmembrane adapter proteins.
Immunol Rev. 2008 Aug;224:215-28; IF=9.542, times cited=25
12. Posevitz-Fejfar A, Smida M, Kliche S, Hartig R, Schraven B, Lindquist JA. A displaced
PAG enhances proximal signaling and SDF-1 induced T-cell migration. Eur J Immunol.
2008 Jan;38(1):250-9; IF=4.179, times cited=24
13. Smida M, Posevitz-Fejfar A, Horejsi V, Schraven B, Lindquist JA. A novel negative
regulatory function of the phosphoprotein associated with glycosphingolipid-enriched
microdomains: blocking Ras activation. Blood. 2007 Jul 15;110(2):596-615; IF=11.847,
times cited=61
14. Filby A., Seddon B, Kleczkowska J, Salmond R, Tomlinson P, Smida M, Lindquist JA,
Schraven B, Zamoyska R. Fyn regulates the duration of T cell receptor engagement
needed for commitment to effector function. J Immunol. 2007 Oct 1;179(7):4635-44;
IF=4.985, times cited=55
15. Simeoni L, Smida M, Posevitz V, Schraven B, and Lindquist JA. Right time, right place:
the organization of membrane proximal signaling. Semin Immunol. 2005 Feb;17(1):35-
49; IF=8.461, times cited=26
Abstracts in journals
1. Smida M, Kozlova V, Vakulova V, Ledererova A, Doubek M, Mayer J, Pospisilova S.
Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy
in B-Lymphoid Malignancies. Blood (2016);128:3968
2. Staňo Kozubík K., Pál K., Radová L., Šmída M., Réblová K., Plevová K., Pospíšilová
Š., Doubek M. Využití celoexomového sekvenování. Transfuze a hematologie dnes
(2016);22(s):89.
3. Smida M, Fece de la Cruz F, Uras I, Nijman SMB. Systematic analysis of gene-drug
interactions in isogenic cells reveals novel unexpected dependencies in lung cancer
cells. Mol Cancer Ther (2013);12(5 Suppl): A25
4. Fece de la Cruz F, Smida M, Nijman SMB. A Functional Pharmacogenetic Screen in
Non-small Cell Lung Adenocarcinoma. European Journal of Cancer (2012);48:
s234
Junior RGL application M. Šmída
8
5. RESEARCH CAREER
I obtained my PhD in the lab of Prof. Burkhart Schraven at the Institute of Molecular and
Clinical Immunology in Magdeburg (Germany) under the direct supervision of Dr. Lindquist.
Here, I received a deep insight into the field of T-cell immunity as well as a very broad
knowledge of cellular signaling pathways and I successfully employed a broad range of cell
biology, biochemistry and molecular biology techniques. I studied signaling pathways at the
level of membrane proximal scaffolds and their impact upon Src kinases, but also elucidated
novel modes of regulation of Ras-MAPK signaling. Thus, I focused on the regulatory
pathways of two main oncogenes – Src and Ras, and investigated mechanisms of
oncogene-induced senescence and transcription factor activation in the nucleus. During this
project, I further managed a fruitful collaboration with Prof. Hořejší (Prague, CZ).
As a post-doc, I discovered the role of a previously uncharacterized protein as a GTPaseactivating
protein for Rho family GTPases involved in T-cell activation and cytoskeleton
reorganization. We have generated knockout mouse in order to study the function in vivo
(manuscript in preparation). To investigate a putative role of this protein in leukemia, I
initiated a collaboration with the Hematology department at the Medical University
Magdeburg to utilize bone marrow biopsies from patients.
My interdisciplinary and collaborative spirit also led to a cooperation with Dr Jürgen Kraus
from the Department of Pharmacology and Toxicology at the Medical University Magdeburg
in order to test the effects of neuromodulators like opioids and cannabinoids on the immune
system. This project was established and performed independently of my PhD supervisor. I
also participated in a SYBILLA consortium (FP7, coordinated by Dr. Schamel, Freiburg,
Germany) to investigate T-cell activation in health and disease from a systems biology
perspective, which gave me the opportunity to work together with highly recognized experts
in the field.
I then took up a challenging senior post-doctoral position at the prestigious Centre for
Molecular Medicine (CeMM) of the Austrian Academy of Sciences in Vienna, Austria. Here, I
made my transition from basic research to a translational science and expanded my
knowledge of intracellular signaling pathways with the focus on oncogenic transformation. I
familiarized myself with the techniques required to study tumorigenesis and learned how to
tackle drug sensitivities or resistances triggered by cellular mutations. I performed several
high-throughput screens with small-molecule compounds, searching for functional gene-drug
interactions primarily based on the principles of synthetic lethality. Thereby, I identified ATM
mutation as mutation sensitizing lung tumors specifically to clinically interesting inhibitors of
MEK kinases. As MEK inhibitors are currently in numerous clinical trials, we proposed to use
ATM mutation status as the biomarker stratifying patients for the treatment with these drugs.
These exciting results were recently published in Nature Communications. At CeMM, I
learned many diverse state-of-the-art techniques, among others RNA-sequencing and
CRISPR/Cas9 technology, which I successfully employed in my last project. I learned how to
use the gene editing CRISPR/Cas9 system to generate gene knockouts or gene knock-ins at
a specific residue and became familiar with diverse techniques used to analyze edited
genes. Additionally, I gained experience with diverse mouse xenograft models and
techniques associated with in vivo studies.
In June 2014, I accepted a position of an independent junior researcher at CEITEC MU in the
Molecular Medicine program led by Prof. Š. Pospíšilová. Here, I started working in the field of
Junior RGL application M. Šmída
9
personalized medicine for B-cell malignancies. I started to investigate mechanisms of
resistance to modern therapies as well as predicting novel targeted treatments. I launched
and equipped BSL-2 (biosafety level 2) cell culture laboratory, where I established the
technique of lentiviral production and lentiviral infection of mammalian cells. In addition, I
established the technique of CRISPR/Cas9 gene editing in the laboratory of Medical
Genomics and introduced this technology to the other labs within the Molecular Medicine
program. I obtained a grant from the Ministry of Health of the Czech Republic to assess
resistance mechanisms to monoclonal antibody therapy and to develop novel intervention
strategies. I assembled my own group of four PhD students and two Master students and
started several important collaborations (see below).
Junior RGL application M. Šmída
10
6. RESEARCH PLAN
My extensive international lab experience helped me to gain profound knowledge of diverse
molecular biology techniques that I plan to establish in my own laboratory at CEITEC. At the
moment, I am evolving my team into three major directions, which are distinct but their
unifying theme is the use of the same high-tech techniques. My laboratory is thus
predominantly technology driven, focusing on the use of lentiviral vectors, gene editing
CRISPR/Cas9 technology, drug and CRISPR/Cas9 screens, synthetic lethality, nextgeneration
sequencing and different functional analyses. Although many of the experiments
are initially planned in B-lymphoid malignancies, all the techniques are very universal and
may be applied to any other cellular system in the future. There are three main projects being
developed that are planned to go on for (at least) next three years:
1) Mechanisms of resistance to monoclonal antibodies (AZV grant)
This project focuses on monoclonal antibody (mAb) therapy in B-lymphoid malignancies (Bcell
lymphoma, B-cell chronic lymphocytic leukemia (CLL)). Therapy with mAbs is the gold
standard in treatment of these diseases, however, it often fails due to the loss of the cognate
antigen targeted by these mAbs. We are investigating the cellular mechanisms responsible
for regulation of expression of these antigens. Better understanding of these mechanisms
can help us to predict and/or counteract the disappearance of the antigens. We are planning
to perform RNA sequencing in our generated mAb-resistant cell lines to identify changes in
expression profiles imposed by the antigen loss. We will elucidate epigenetic changes (i.e.
DNA methylation, histone acetylation and methylation) triggered in these cells. Techniques
like bisulfite sequencing and chromatin immunoprecipitation will be implemented.
Furthermore, we aim to identify novel intervention strategies that would maintain the
expression of the antigens, thereby improving the efficacy of the mAbs. We will make use of
the CRISPR/Cas9 technology, which is simple, versatile, state-of-the-art technique
developed to induce DNA modifications in any desired gene loci. We have obtained a
collection of CRISPR guide RNAs targeted against almost the whole human genome and will
apply this library on our resistant cell lines or cell lines with intrinsically low expression of the
mAb antigens. Sorting the cells that will upregulate the antigens of interest and sequencing
their edited loci will reveal the identity of genes that are able to regulate the expression of
desired antigens. These identified genes will be validated, verified in primary cells and the
underlying mechanisms elucidated. Drugs inhibiting the revealed gene(s) will be obtained
and used to corroborate the findings also in an in vivo mouse model.
For proper implementation of this project, intense collaboration with the Central Genomics
core facility will be crucial as well as cooperation with the Animal facility located within the
university campus Bohunice. To accomplish the mechanistic studies, we envision the use of
the Cellular imaging core facility and the Proteomics core facility to investigate
subcellular localizations and protein-protein associations or protein phosphorylations.
2) Functional CRISPR/Cas9 genomics to reveal novel vulnerabilities as therapy targets
Here we aim to propose novel opportunities for targeted therapy by screening a panel of
isogenic cell lines, i.e. differing in just one genetic aberration. Screening isogenic cell lines
has the advantage that the observed phenotype can directly be attributed to the introduced
genetic change. As a model disease, B-CLL was chosen as it was shown to be characterized
by a variety of distinct somatic aberrations with the lack of any therapeutic biomarkers and
limited targeted treatments. We have selected ten most prevalent aberrations recurrently
found in CLL patients and will introduce these into a CLL cell line through specific
CRISPR/Cas9 gene editing, thereby generating ten isogenic cell lines. These isogenic lines
Junior RGL application M. Šmída
11
will then be used to screen against whole-genome CRISPR/Cas9 knockout library. Nextgeneration
sequencing (done jointly with Central Genomics) of the cell population after 14day
incubation period versus day 0 will reveal the identity of genes whose deletion leads to
reduction in cell viability. Focusing on genes specific for single isogenic cell line will identify
unique vulnerability explicitly for given genetic aberration. Identified genes will again be
profoundly validated and confirmed on primary cells. Mechanisms underlying observed
sensitivities will be investigated through a variety of molecular biology and cellular
techniques. Here again we envision possible need for phosphoproteomic analysis or proteinprotein
interactions elucidation performed at the Proteomics core facility.
The main aim will be to identify a drug inhibiting the revealed gene product conferring the
specific sensitivity. In this respect, we might team up with the lab of Dr. Kubicek at CeMM
(Vienna, Austria) or assoc. prof. Hajduch at IMTM (Olomouc, CZ), who both possess large
scale drug libraries and high-throughput drug screening facilities. Shall we identify only a tool
compound, we may perform further drug optimization through medicinal chemistry
approaches in cooperation with Dr. Huber at the Nuffield Department of Medicine (Oxford,
UK). Finally, we will transfer our findings into an in vivo setting by performing the experiments
in an appropriate CLL mouse model.
3) Chimeric antigen receptor T cells
Together with prof. Mayer (Department of Internal Medicine - Hematology and Oncology,
Faculty of Medicine and University Hospital Brno) and prof. Štěrba (Clinic of Children
Oncology) we have initiated a novel project to establish and optimize an innovative and
exciting technology of Chimeric Antigen Receptor (CAR) T cells. These are patient´s
autologous T cells that are genetically modified to carry a chimeric antigen receptor
consisting of an extracellular antibody fragment (specific for a given antigen) fused to
intracellular T-cell receptor signaling domains. Introduction of such a receptor reprograms
patient´s T cells to specifically identify and kill only tumor cells expressing defined antigen.
We plan to establish this technology in our laboratory, develop novel and improved designs
of CAR constructs, lentivirally introduce them into T cells and exhaustively characterize
generated products. In addition, we shall attempt to tackle some troubles of this therapy by
producing allogeneic CAR-T cells, in which the endogenous TCR will be deleted by
CRISPR/Cas9 system. The in vitro studies will again be followed by careful in vivo
validations on mouse models. Finally, we will initiate intensive discussions with SÚKL (State
Institute for Drug Control) to obtain permission for transferring this technology into clinic. We
plan to establish CAR-T cells generation in our Cleanroom facility at the University
campus or at the ICRC at St Anna Hospital (CTEU-cGMP facility) to be able to offer this to
the patients at the University Hospital in the frame of a clinical trial.
Beside these projects, I am establishing several other important collaborations. As part of the
cooperation with the team of prof. Doubek (IHOK, University Hospital Brno), we will be
performing functional validations of diverse gene mutations that they identify in their
thrombocytopenia patients. We have already initiated a collaboration with prof. Veselská
(Department of Experimental Biology) to help her team with the use of lentiviral infection for
knock-down and overexpression studies using specific transcription factors.
As I established the lentiviral technology in our cell culture laboratory, we have immediately
introduced this technique to the members of research groups of Mary O´Connell, Marek
Mráz and Ondřej Slabý. We have also trained them how to use the CRISPR/Cas9
technology and I am sure we will continue to join our efforts on this topic also in future. As it
is very elegant technique, we will be happy to cooperate with any other labs and are very
open for any new and exciting projects.
Junior RGL application M. Šmída
12
7. REFEREES
PD Dr. Jonathan A. Lindquist (PhD supervisor)
Clinic of Nephrology and Hypertension, Diabetes and Endocrinology
Otto-von-Guericke University
Hs.60b/R2783
Leipziger Str. 44
D-39120 Magdeburg
Germany
Tel. +49-391-67-21744
Fax. +49-391-67-24709
jon.lindquist@med.ovgu.de
Prof. Dr. Sebastian Nijman (Postdoc supervisor)
University of Oxford
Nuffield Department of Medicine (NDM)
Ludwig Cancer Research Institute
Target Discovery Institute (TDI)
NDM Research Building (NDMRB)
Old Road Campus
Roosevelt Drive, Headington
Oxford, OX3 7FZ
United Kingdom
sebastian.nijman@gmail.com